Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as "Nasu-Hakola disease," is a globally distributed recessively inherited disease leading to death during the 5th decade of life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations in TYROBP. Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2 forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex result in an identical human disease phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygous loss-of-function mutations in TREM2 or DAP12 genes cause Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [39]
In the citing paper
“TYROBP is a transmembrane adaptor protein for TREM2, SIRPβ1, and CR3 receptors, which are known to be involved in AD pathogenesis [90–92].”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [92]
In the citing paper
“Homozygous Q33X, Y38C and T66M variants have been identified in patients with Nasu-Hakola disease [44, 47, 95].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“A number of mutations in PLCG2 (about 75%), that have been previously implicated in various inflammatory diseases [92–102], actually map to the autoinhibitory interface on the PLCγ2 model structure and can be considered as pathogenic (Fig. 2c)”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“Even more rare loss-of-function mutations of TREM2 or DAP12 cause a form of recessively inherited presenile dementia, called Nasu-Hakola disease (126, 127).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [126]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284 · cited 4×
“2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather than in acute, inflammation (Bouchon et al. 2000).”
BackgroundInfluentialTREM-1 amplifies inflammation and is a crucial mediator of septic shock
Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001) · Nature · doi:10.1038/35074114 · Cited by 1,090 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundImmunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialVitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748 · cited 1×
“1) (Vitale et al. 1998), MDL1 (chromosome 7q33) (Bakker et al. 1999), CD94 (chromosome 12p13.”
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 6×
“Interestingly, patients with PLOSL who are homozygous for mutations in either TREM2 or TYROBP display identical CNS and bone manifestations (table 2)—and no immunological symptoms (Paloneva et al. 2000).”
BackgroundInfluentialSelf-citationBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundLy-49D and Ly-49H associate with mouse DAP12 and form activating receptors.
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · PubMed · Cited by 277
Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.7 · Cited by 249 · cited 1×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundMutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R. F., Sujansky, E., Bale, S. J., & Muenke, M. (2002) · Human Genetics · doi:10.1007/s00439-002-0695-5 · Cited by 244
Research works printed but not linked: 1
- Tranebjærg, 2000, Polycystic lipomembranous osteodysplasia, Tidsskr Nor Laegeforen, 120, 3196
Cited by
Items 201–300 of 694
Ruiz, A., Dols-Icardo, O., Bullido, M. J., Pastor, P., Rodríguez-Rodríguez, E., López de Munain, A., de Pancorbo, M. M., Pérez-Tur, J., Álvarez, V., Antonell, A., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.011 · Cited by 118
“Nasu-Hakola disease, which is mainly characterized by pre-senile FTD and cystic bone lesions (Paloneva et al. 2002).”
BackgroundEssential Role of DAP12 Signaling in Macrophage Programming into a Fusion-Competent State
Helming, L., Tomasello, E., Kyriakides, T. R., Martinez, F. O., Takai, T., Gordon, S., & Vivier, E. (2008) · Science Signaling · doi:10.1126/scisignal.1159665 · Cited by 116
“In humans, mutation of either DAP12 or TREM-2 results in PLOSL (also known as Nasu-Hakola syndrome), a rare disease characterized by presenile dementia, bone cysts, and impaired osteoclast differentiation (15, 25, 45).”
BackgroundAminophospholipids are signal-transducing TREM2 ligands on apoptotic cells
Shirotani, K., Hori, Y., Yoshizaki, R., Higuchi, E., Colonna, M., Saito, T., Hashimoto, S., Saito, T., Saido, T. C., & Iwata, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-43535-6 · Cited by 116
Gispert, J. D., Suárez‐Calvet, M., Monté, G. C., Tucholka, A., Falcon, C., Rojas, S., Rami, L., Sánchez‐Valle, R., Lladó, A., Kleinberger, G., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.005 · Cited by 115
“Homozygous mutations in TREM2 cause Nasu–Hakola disease and frontotemporal-like syndrome, an early-onset recessive form of dementia [25,26].”
BackgroundKiialainen, A., Hovanes, K., Paloneva, J., Kopra, O., & Peltonen, L. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.007 · Cited by 114
Self-citationMa, J., Jiang, T., Tan, L., & Yu, J.-T. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8811-9 · Cited by 113
“However, in some families, no mutation was found in TYROBP suggesting that the disease is characterized by genetic heterogeneity [50].”
BackgroundCrotti, T. N., Dharmapatni, A. A. S. S. K., Alias, E., & Haynes, D. R. (2015) · Journal of Immunology Research · doi:10.1155/2015/281287 · Cited by 117
Neuroprotective Effect of TREM-2 in Aging and Alzheimer’s Disease Model
Raha, A. A., Henderson, J. W., Stott, S. R. W., Vuono, R., Foscarin, S., Friedland, R. P., Zaman, S. H., & Raha-Chowdhury, R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160663 · Cited by 111
“Developmental dysregulation of either TREM2 or DAP12 mutation causes an early onset form of dementia with cystic bone disorder, known as Nasu-Hakola disease [30–32].”
Fassler, M., Rappaport, M. S., Cuño, C. B., & George, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01980-5 · Cited by 110
“NHD is a rare autosomalrecessive early-onset dementia characterized by behavioral changes and cognitive decline, with or without pathological bone fractures [2, 3, 13].”
BackgroundThe role of microglia in brain maintenance: implications for Rett syndrome
Derecki, N. C., Cronk, J. C., & Kipnis, J. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.002 · Cited by 100
TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers
Del-Aguila, J. L., Benitez, B. A., Li, Z., Dube, U., Mihindukulasuriya, K. A., Budde, J. P., Farias, F. H. G., Fernández, M. V., Ibanez, L., Jiang, S., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0319-3 · Cited by 109
“Homozygous loss-of-function mutations in TREM2 or DAP12 cause a rare and fatal disease known as Nasu-Hakola disease (NHD) or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) which is characterized by an early-onset frontotemporal dementia-like phenotype and bone cysts [6, 7].”
BackgroundMicroglia in Alzheimer’s disease: A target for immunotherapy
Wang, S., & Colonna, M. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0818-319r · Cited by 105
Ishida-Kitagawa, N., Tanaka, K., Bao, X., Kimura, T., Miura, T., Kitaoka, Y., Hayashi, K., Sato, M., Maruoka, M., Ogawa, T., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.324194 · Cited by 105
“Of note, genetic defects in human DAP12 and TREM2 result in a rare syndrome characterized by bone cysts and presenilin dementia called polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, also known as Nasu-Hakola disease (37, 38).”
BackgroundTREM2 triggers microglial density and age-related neuronal loss
Linnartz‐Gerlach, B., Bodea, L., Klaus, C., Ginolhac, A., Halder, R., Sinkkonen, L., Walter, J., Colonna, M., & Neumann, H. (2019) · Glia · doi:10.1002/glia.23563 · Cited by 104
“Loss-of-function mutations of TREM2 and TYROBP have been linked to development of Nasu–Hakola disease (NHD; Paloneva et al., 2000, 2002), an inflammatory degenerative disease of the brain and bone, leading to premature dementia and death (Bianchin, Martin, de Souza, de Oliveira, & Rieder, 2010).”
BackgroundThrash, J. C., Torbett, B. E., & Carson, M. J. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9657-1 · Cited by 110
“Despite broad expression within the immune system, functional DAP12 deficiency in humans does not lead to overt widespread deficiencies and/or dysfunction in the immune system [4].”
BackgroundRoussos, P., Katsel, P., Fam, P., Tan, W., Purohit, D. P., & Haroutunian, V. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.013 · Cited by 103
“The STG was selected as the region of interest as: (i) it demonstrated the most significant increase in NP in TREM2 ADcarriers compared with ADnoncarriers (see below); (ii) it shows profound transcriptional vulnerability in gene expression microarray studies in AD [15]; and (iii) there is abundant expression of TREM2…”
BackgroundEngineering an inhibitor-resistant human CSF1R variant for microglia replacement
Chadarevian, J. P., Lombroso, S. I., Peet, G. C., Hasselmann, J., Tu, C., Marzan, D. E., Capocchi, J., Purnell, F. S., Nemec, K. M., Lahian, A., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220857 · Cited by 95
“…Blurton-Jones, 2019; Kim et al., 2020; Podle´sny-Drabiniok et al., 2020; Amin et al., 2022) and “ primary microgliopathies, ” rare diseases arising from mutations that alter microglial function and survival (Paloneva et al., 2002; Konno et al., 2018; Berdowski et al., 2021; Macintosh et al., 2022).”
Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis.
Gibot, S. (2005) · Critical Care · doi:10.1186/cc3732 · Cited by 116
“TREM-1 has been implicated in mounting the inflammatory response, whereas TREM-2 regulates dendritic cells, osteoclasts and microglia [6,8,9].”
BackgroundNeuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis
Azzolini, F., Gilio, L., Pavone, L., Iezzi, E., Dolcetti, E., Bruno, A., Buttari, F., Musella, A., Mandolesi, G., Guadalupi, L., et al. (2022) · Biomolecules · doi:10.3390/biom12020222 · Cited by 109
“TREM-2 is a surface receptor expressed by microglial cells [30].”
BackgroundGuo, Y., Wei, X., Yan, H., Qin, Y., Yan, S., Liu, J., Zhao, Y., Jiang, F., & Lou, H. (2019) · The FASEB Journal · doi:10.1096/fj.201900992r · Cited by 101
“TREM2 mutation has been identified as a risk factor for several neurodegenerative diseases, including Nasu-Hakola disease (7, 8), Alzheimer disease (9, 10), and PD (11–13).”
BackgroundÖhrfelt, A., Axelsson, M., Malmeström, C., Novakova, L., Heslegrave, A., Blennow, K., Lycke, J., & Zetterberg, H. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515624558 · Cited by 98
“This rare disorder is characterized by demyelination of the CNS, presenile dementia and bone cysts.(6) Recently, genome-wide association studies have also shown that rare variants in the TREM2 gene are associated with an increased risk of Alzheimer’s disease.”
BackgroundHigh dose M‐CSF partially rescues the Dap12−/− osteoclast phenotype
Faccio, R., Zou, W., Colaianni, G., Teitelbaum, S. L., & Patrick Ross, F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10694 · Cited by 98
“More recent studies reveal further heterogeneity in NHD in that a number of affected patients have normal DAP12 expression, but functionally relevant mutations in TREM2 [Paloneva et al., 2002; Cella et al., 2003].”
BackgroundMerck, E., Gaillard, C., Gorman, D. M., Montero-Julian, F., Durand, I., Zurawski, S. M., Menetrier-Caux, C., Carra, G., Lebecque, S., Trinchieri, G., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0850 · Cited by 92
TREM2 is required for microglial instruction of astrocytic synaptic engulfment in neurodevelopment
Jay, T. R., von Saucken, V. E., Muñoz, B., Codocedo, J. F., Atwood, B. K., Lamb, B. T., & Landreth, G. E. (2019) · Glia · doi:10.1002/glia.23664 · Cited by 97
“PLOSL) (Paloneva et al., 2002), a progressive neurodegenerative disease characterized by white matter loss, psychosis and dementia (Hakola, 1972; Nasu, Tsukahara, & Terayama, 1973).”
BackgroundJendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94
TREM2 in Alzheimer’s Disease: Microglial Survival and Energy Metabolism
Zheng, H., Cheng, B., Li, Y., Li, X., Chen, X., & Zhang, Y.-W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00395 · Cited by 94
The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases
Singleton, A., & Hardy, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.040 · Cited by 91
DAP12: an adapter protein with dual functionality
Takaki, R., Watson, S. R., & Lanier, L. L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00466.x · Cited by 93
“Notably, humans with mutated TREM-2 or DAP12 develop Nasu-Hakola syndrome or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, a rare disease characterized by brain degeneration and osteopetrosis, which causes presenile dementia and bone cysts, respectively (29, 30).”
BackgroundIizasa, E., Chuma, Y., Uematsu, T., Kubota, M., Kawaguchi, H., Umemura, M., Toyonaga, K., Kiyohara, H., Yano, I., Colonna, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22620-3 · Cited by 92
TREM2/DAP12 Complex Regulates Inflammatory Responses in Microglia via the JNK Signaling Pathway
Zhong, L., Zhang, Z.-L., Li, X., Liao, C., Mou, P., Wang, T., Wang, Z., Wang, Z., Wei, M., Xu, H., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00204 · Cited by 83
“Notably, loss-of-function mutations of either DAP12 or TREM2 result in a disorder known as Nasu-Hakola disease (NHD; Paloneva et al., 2000, 2002).”
BackgroundInflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update
Zhang, Z.-G., Li, Y., Ng, C. T., & Song, Y.-Q. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0351-0 · Cited by 86
“Its signaling capacity is carried out through forming a complex with the TYRO protein tyrosine kinase binding protein (TYROBP, also known as DAP12) (Paloneva et al. 2002).”
BackgroundTREM2 and sTREM2 in Alzheimer’s disease: from mechanisms to therapies
Zhang, L., Xiang, X., Li, Y., Bu, G., & Chen, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00834-z · Cited by 97
Pelham, C. J., & Agrawal, D. K. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.866519 · Cited by 97
Microglia and brain macrophages: An update
Sasaki, A. (2017) · Neuropathology · doi:10.1111/neup.12354 · Cited by 92
“The molecular background of NHD was characterized by identifying mutations in two genes: DAP12, also known as TYRO protein tyrosine kinasebinding protein (TYROBP) and TREM2.”
BackgroundITAM-based signaling beyond the adaptive immune response
Fodor, S., Jakus, Z., & Mócsai, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.11.001 · Cited by 102
Oosterhof, N., Holtman, I. R., Kuil, L. E., van der Linde, H. C., Boddeke, E., Eggen, B. J. L., & van Ham, T. J. (2016) · Glia · doi:10.1002/glia.23083 · Cited by 94
“In addition, they play an important role in many neurodegenerative diseases, as scavengers of pathogens, debris and dead cells, and as regulators of immune responses (Hanisch and Kettenmann, 2007; Paloneva et al., 2002; Prinz et al., 2011).”
BackgroundWhite matter microglia heterogeneity in the CNS
Amor, S., McNamara, N. B., Gerrits, E., Marzin, M. C., Kooistra, S. M., Miron, V. E., & Nutma, E. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02389-x · Cited by 89
Phagocytic astrocytes: Emerging from the shadows of microglia
Konishi, H., Koizumi, S., & Kiyama, H. (2022) · Glia · doi:10.1002/glia.24145 · Cited by 88
A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature
Dardiotis, E., Siokas, V., Pantazi, E., Dardioti, M., Rikos, D., Xiromerisiou, G., Markou, A., Papadimitriou, D. A., Speletas, M. G., & Hadjigeorgiou, G. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.015 · Cited by 97
Shifting paradigms: The central role of microglia in Alzheimer’s disease
Schwabe, T., Srinivasan, K., & Rhinn, H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104962 · Cited by 84
“While Apoe is a ligand for Trem2 indicating that it acts upstream, Apoe also appears to be downstream of Trem2 signaling, as its expression and secretion around plaques are reduced in APP Tg mice lacking Trem2 (Krasemann et al., 2017; Parhizkar et al., 2019; Sala Frigerio et al., 2019).”
BackgroundInfluentialFilipello, F., You, S.-F., Mirfakhar, F. S., Mahali, S., Bollman, B., Acquarone, M., Korvatska, O., Marsh, J. A., Sivaraman, A., Martinez, R., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02568-y · Cited by 81
“CCL3 is a neutrophil chemoattractant and a direct stimulator of osteoclastogenesis, a process that together with bone remodeling is controlled by TREM2/DAP12 signaling and is altered in NHD patients [10, 63, 70, 75].”
BackgroundInfluentialLatest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease
Milà-Alomà, M., Suárez-Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78
Walter, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.704981 · Cited by 80
“It is interesting to note that senile plaques and neurofibrillary tangles have been observed in a brain autopsy of a 48-year-old patient clinically diagnosed with NHD and a homozygous mutation in TREM2 (90, 91), suggesting that impaired TREM2 signaling might be sufficient to induce the two major neuropathological hall…”
BackgroundLynch, D. S., Jaunmuktane, Z., Sheerin, U.-M., Phadke, R., Brandner, S., Milonas, I., Dean, A., Bajaj, N., McNicholas, N., Costello, D., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-310788 · Cited by 81
“17 Heterozygous variants in TREM2 are also a signi fi cant risk factor for Alzheimer ’ s disease (AD), 18 and genome-wide association studies have linked variants in the microglial receptors CD33 and IRF8 with AD and multiple sclerosis, respectively.”
Galectin-3 controls the response of microglial cells to limit cuprizone-induced demyelination
Hoyos, H. C., Rinaldi, M., Mendez-Huergo, S. P., Marder, M., Rabinovich, G. A., Pasquini, J. M., & Pasquini, L. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.023 · Cited by 73
Hiruma, Y., Tsuda, E., Maeda, N., Okada, A., Kabasawa, N., Miyamoto, M., Hattori, H., & Fukuda, C. (2012) · Bone · doi:10.1016/j.bone.2012.11.036 · Cited by 83
“DNAX-activating protein of 12 kDa (DAP12) is one such ITAM-bearing adaptor; its deficiency is reportedly associated with skeletal abnormalities in mice and humans, suggesting the involvement of this signaling pathway in regulating osteoclast development and/ or function [15–19].”
BackgroundGene expression profiling of the preclinical scrapie-infected hippocampus
Brown, A. R., Rebus, S., McKimmie, C. S., Robertson, K. A., Williams, A., & Fazakerley, J. K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.060 · Cited by 88
“DAP12, which is present on natural killer (NK) cells and myeloid cells, forms a receptor signalling complex in conjunction with TREM2 (triggering receptor expressed on myeloid cells 2b) [12].”
BackgroundThe TREM2-DAP12 signaling pathway in Nasu–Hakola disease: a molecular genetics perspective
Humphrey, M. B., Xing, J., & Titus, A. (2015) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s58057 · Cited by 77
“13 TREM2 is detected in microglia associated with neurons and in microglial clusters.”
BackgroundInfluentialPoon, C. H., Wang, Y., Fung, M.-L., Zhang, C., & Lim, L. W. (2020) · Aging and disease · doi:10.14336/ad.2019.1026 · Cited by 73
“For example, the TREM2-BAC x 5XFAD mouse model was generated to probe TREM2, a microglia-enriched gene associated with a recessive disease named Nasu-Hakola disease, which is characterized by bone cysts and early dementia [83].”
MethodNataf, S., Anginot, A., Vuaillat, C., Malaval, L., Fodil, N., Chereul, E., Langlois, J., Dumontel, C., Cavillon, G., Confavreux, C., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62251-1 · Cited by 79
Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
Thomas, L., & Pasquini, L. A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00297 · Cited by 76
“, 2001), which presents progressive presenile dementia and sclerosing leukoencephalopathy driven by lower microglial phagocytic activity (Paloneva et al., 2002).”
BackgroundAn Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene
Soragna, D. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.825-a · Cited by 75
TREM2 expression in the human brain: a marker of monocyte recruitment?
Fahrenhold, M., Rakic, S., Classey, J., Brayne, C., Ince, P. G., Nicoll, J. A. R., Boche, D., & MRC‐CFAS (2018) · Brain Pathology · doi:10.1111/bpa.12564 · Cited by 76
“The importance of TREM2 in brain function has been illustrated by the autosomal recessive disorder Nasu-Hakola disease (NHD) due to homozygous loss-of-function mutations in the TREM2 gene (11, 32), in which affected people develop a presenile frontotemporal dementia with sclerosing leukoencephalopathy and polycystic l…”
BackgroundThe receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity
Ramirez-Ortiz, Z. G., Prasad, A., Griffith, J. W., Pendergraft, W. F., Cowley, G. S., Root, D. E., Tai, M., Luster, A. D., El Khoury, J., Hacohen, N., et al. (2015) · Nature Immunology · doi:10.1038/ni.3143 · Cited by 71
Review: The genetics of Alzheimer's disease; putting flesh on the bones
Medway, C., & Morgan, K. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12101 · Cited by 67
Role of OSCAR Signaling in Osteoclastogenesis and Bone Disease
Nedeva, I. R., Vitale, M., Elson, A., Hoyland, J. A., & Bella, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641162 · Cited by 73
Delbridge, A. R. D., Huh, D., Brickelmaier, M., Burns, J. C., Roberts, C., Challa, R., Raymond, N., Cullen, P., Carlile, T. M., Ennis, K. A., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592005 · Cited by 72
Exploring the Impact of TREM2 in Tumor-Associated Macrophages
Khantakova, D., Brioschi, S., & Molgora, M. (2022) · Vaccines · doi:10.3390/vaccines10060943 · Cited by 75
Heredofamilial Brain Calcinosis Syndrome
Baba, Y., Broderick, D. F., Uitti, R. J., Hutton, M. L., & Wszołek, Z. K. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.5.641 · Cited by 78
Recent Advances in the Genetics of Frontotemporal Dementia
Sirkis, D. W., Geier, E. G., Bonham, L. W., Karch, C. M., & Yokoyama, J. S. (2019) · Current Genetic Medicine Reports · doi:10.1007/s40142-019-0160-6 · Cited by 68
Wang, X.-Q., Tao, B.-B., Li, B., Wang, X.-H., Zhang, W.-C., Wan, L., Hua, X.-M., & Li, S.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.6221 · Cited by 67
“Mutations of TREM2 cause skeletal and psychotic abnormalities called Nasu-Hakola disease (NHD) [8], or a neurodegenerative disorder characterized by numerous deficits in neurotransmitter function called Alzheimer’s disease [9].”
BackgroundKcnn4 Is a Regulator of Macrophage Multinucleation in Bone Homeostasis and Inflammatory Disease
Kang, H., Kerloc’h, A., Rotival, M., Xu, X., Zhang, Q., D’Souza, Z., Kim, M. S., Scholz, J. A. C., Ko, J., Srivastava, P. K., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.032 · Cited by 72
“In humans, deletions or loss-of-function mutations in either the TYROBP (DAP12) or TREM2 genes are causally associated with Nasu-Hakola disease (Paloneva et al., 2000, 2002), where defective multinucleation in osteoclasts results in impaired bone resorption (Humphrey et al., 2004).”
BackgroundTada, M., Konno, T., Tada, M., Tezuka, T., Miura, T., Mezaki, N., Okazaki, K., Arakawa, M., Itoh, K., Yamamoto, T., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24754 · Cited by 70
“NHD is a human disease caused by recessive loss-of-function mutations in DAP12 or the associated cell-surface receptor TREM2.”
BackgroundIFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation
Sosa, R. A., Murphey, C., Robinson, R. R., & Forsthuber, T. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505955112 · Cited by 68
“TREM2 is known to interact with the signaling adapter protein DAP12 (DNAX-activation protein of 12 kDa) (53); however its ligand in apoptotic cells and other cellular debris is unknown.”
BackgroundThe innate immune system in Alzheimer's disease
Boutajangout, A., & Wisniewski, T. (2013) · International Journal of Cell Biology · doi:10.1155/2013/576383 · Cited by 69
“TREM2 is a phagocytic receptor of bacteria [11] and forms a receptor signaling complex with the TYRO protein tyrosine kinase binding protein (TYROBP, also called DAP12), that triggers phagocytosis and the release of reactive oxygen species [21].”
BackgroundNasu–Hakola disease and primary microglial dysfunction
Bianchin, M. M., Martin, K. C., de Souza, A. C., de Oliveira, M. A., & de Mello Rieder, C. R. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17-c1 · Cited by 69
Self-citationTrem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice
Jadhav, V. S., Lin, P. B. C., Pennington, T., Di Prisco, G. V., Jannu, A. J., Xu, G., Moutinho, M., Zhang, J., Atwood, B. K., Puntambekar, S. S., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00409-0 · Cited by 70
Kaneko, M., Sano, K., Nakayama, J., & Amano, N. (2010) · Neuropathology · doi:10.1111/j.1440-1789.2010.01127.x · Cited by 67
“In recent years, studies have demonstrated that NHD is caused by a mutation in the DAP12 gene (DNAX-activating protein 12) (TYROBP: TYRO protein tyrosine kinase binding protein, KARAP: killer-cell activating receptor associated protein) or the TREM2 gene (triggering receptor expressed on myeloid cells 2).(3,4) The pre…”
BackgroundOsteoclasts—the innate immune cells of the bone
Wu, Y., Humphrey, M. B., & Nakamura, M. C. (2008) · Autoimmunity · doi:10.1080/08916930701693180 · Cited by 67
“[68] Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R,”
BackgroundImmunohistochemical characterization of microglia in Nasu‐Hakola disease brains
Satoh, J., Tabunoki, H., Ishida, T., Yagishita, S., Jinnai, K., Futamura, N., Kobayashi, M., Toyoshima, I., Yoshioka, T., Enomoto, K., et al. (2011) · Neuropathology · doi:10.1111/j.1440-1789.2010.01174.x · Cited by 66
“Nasu-Hakola disease is caused by loss-of-function mutations of DAP12 or TREM2.(6,7) TREM2 and DAP12 constitute a receptor/adapter signaling complex expressed on osteoclasts, DC, macrophages and microglia.”
BackgroundInfluentialTREM2 Variants and Neurodegenerative Diseases: A Systematic Review and Meta-Analysis
Zhou, S.-L., Tan, C.-C., Hou, X.-H., Cao, X.-P., Tan, L., & Yu, J.-T. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181038 · Cited by 70
“TREM2 polymorphisms are not only related to common neurodegenerative diseases, such as AD, PD, and FTD, but have already been discovered in PLOSL (a familial genetic disorder, characterized by presenile dementia, bone cysts, and spontaneous bone fractures) [42].”
Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases
Angata, T. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0610-1 · Cited by 68
Zhou, Y., Tada, M., Cai, Z., Andhey, P. S., Swain, A., Miller, K. R., Gilfillan, S., Artyomov, M. N., Takao, M., Kakita, A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01403-y · Cited by 69
Hebron, M. L., Peyton, M. A., Liu, X., Gao, X., Wang, R., Lonskaya, I., & Moussa, C. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.07.009 · Cited by 76
Divergent Neuroinflammatory Regulation of Microglial TREM Expression and Involvement of NF-κB
Owens, R., Grabert, K., Davies, C. L., Alfieri, A., Antel, J. P., Healy, L. M., & McColl, B. W. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00056 · Cited by 54
“This is a fatal presenile dementia, also presenting with bone pathology, caused by homozygous loss of function mutations in TREM2 (or DAP12) affecting the microglial and ostecoclast myeloid lineages (Paloneva et al., 2000, 2001, 2002).”
BackgroundCao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Targeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 63
Magno, L., Bunney, T. D., Mead, E., Svensson, F., & Bictash, M. N. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00436-5 · Cited by 64
Triggering receptor expressed on myeloid cells receptor family modulators: a patent review
Pelham, C. J., Pandya, A. N., & Agrawal, D. K. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.977865 · Cited by 68
“However, patients with PLOSL apparently do not suffer severe immune deficiencies [56].”
BackgroundInfluentialMicroglial Interferon Signaling and White Matter
McDonough, A., Lee, R. V., & Weinstein, J. R. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2307-8 · Cited by 60
“This disorder is characterized by psychotic symptoms and dementia and is associated with diffuse abnormalities in CNS white matter [44].”
Lue, L.-F., Schmitz, C., & Walker, D. G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.050 · Cited by 63
“Autosomal recessive homozygous mutations in TREM2 or its signaling adaptor, DNAX-activating protein of 12 kDa (DAP12) also cause pre-senile dementia with severe bone cyst in a disease called Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL), also known as Nasu Hakola disease (NHD) (P…”
InfluentialAnticancer effects of echinacoside in hepatocellular carcinoma mouse model and HepG2 cells
Ye, Y., Song, Y., Zhuang, J., Wang, G., Ni, J., & Xia, W. G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27063 · Cited by 63
“In addition, research proved that TREM2 mutation may be associated with Nasu‐Hakola disease (Paloneva et al., 2002) and Alzheimer’s disease (Niemitz, 2013).”
BackgroundBehavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal
Kang, S. S., Kurti, A., Baker, K. E., Liu, C.-C., Colonna, M., Ulrich, J. D., Holtzman, D. M., Bu, G., & Fryer, J. D. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx366 · Cited by 62
Rare TREM2 variants associated with Alzheimer’s disease display reduced cell surface expression
Sirkis, D. W., Bonham, L. W., Aparicio, R. E., Geier, E. G., Ramos, E. M., Wang, Q., Karydas, A., Miller, Z. A., Miller, B. L., Coppola, G., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0367-7 · Cited by 61
“Rare homozygous or compound heterozygous mutations in TREM2 cause NHD or an early-onset FTD syndrome without bone involvement [8, 34].”
BackgroundThe Role of Microglia in Prion Diseases: A Paradigm of Functional Diversity
Obst, J., Simon, E., Mancuso, R., & Gómez‐Nicola, D. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00207 · Cited by 63
“Mutations leading to a loss of function in TREM2 or DAP12 underlie the Nasu–Hakola disease, in which patients display progressive presenile dementia (Paloneva et al., 2000, 2002).”
BackgroundDisease-associated microglia in neurodegenerative diseases: Friend or foe?
Cheng, Y.-H., & Ho, M. S.-C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003426 · Cited by 64
“Human genetic studies have linked hypomorphic TREM2 variants to an increased risk of AD, spurring investigations into its role in DAM within the human brain [34,51,90].”
Targeting Alzheimer's disease with gene and cell therapies
Loera‐Valencia, R., Piras, A., Ismail, M.-A.-M., Manchanda, S., Eyjolfsdottir, H., Saido, T. C., Johansson, J., Eriksdotter, M., Winblad, B. G., & Nilsson, P. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12759 · Cited by 60
Sex-specific DNA methylation differences in Alzheimer’s disease pathology
Zhang, L., Young, J. I., Gomez, L., Silva, T. C., Schmidt, M. A., Cai, J., Chen, X., Martin, E. R., & Wang, L. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01177-8 · Cited by 58
Osteoimmunology: the expanding role of immunoreceptors in osteoclasts and bone remodeling
Long, C. L., & Humphrey, M. B. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.59 · Cited by 61
Microglial innate memory and epigenetic reprogramming in neurological disorders
Martins-Ferreira, R., Leal, B., Costa, P. P., & Ballestar, E. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101971 · Cited by 54
Tran, K. M., Kawauchi, S., Kramár, E. A., Rezaie, N., Liang, H. Y., Sakr, J. S., Gomez-Arboledas, A., Arreola, M. A., Cunha, C. D., Phan, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00598-4 · Cited by 50
Numasawa, Y., Yamaura, C., Ishihara, S., Shintani, S., Yamazaki, M., Tabunoki, H., & Satoh, J.-I. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03311.x · Cited by 58
“Nasu–Hakola disease is caused by a structural defect in one of the two genes, DAP12 (TYROBP) or TREM2, both of which induce a clinicopathologically identical phenotype [2,3].”
BackgroundSpastic movement disorder: what is the impact of research on clinical practice?
Dietz, V. (2003) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.6.820-a · Cited by 56
Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes
Thelen, M., Razquín, C., Hernández, I., Gorostidi, A., Sánchez‐Valle, R., Ortega‐Cubero, S., Wolfsgruber, S., Drichel, D., Fließbach, K., Duenkel, T., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.018 · Cited by 59
Genetics and molecular biology of brain calcification
Deng, H., Zheng, W. L., & Jankovic, J. J. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.04.004 · Cited by 57
A Non-inflammatory Role for Microglia in Autism Spectrum Disorders
Edmonson, C. A., Ziats, M. N., & Rennert, O. M. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00009 · Cited by 61
“Additionally, it is known that mutations in DAP12 lead to Nasu– Hakola disease (OMIM# 221770), a rare autosomal recessive disorder characterized by bone abnormalities and adult-onset neuropsychiatric features, such as social disinhibition, distractibility, and lack of appropriate emotionality (25).”
BackgroundOyanagi, K., Kinoshita, M., Suzuki‐Kouyama, E., Inoue, T., Nakahara, A., Tokiwai, M., Arai, N., Satoh, J., Aoki, N., Jinnai, K., et al. (2017) · Brain Pathology · doi:10.1111/bpa.12443 · Cited by 53
“The causative genes are TREM2 (triggering receptor expressed on myeloid cells 2) and DNAX activating protein of 12 kDa (DAP12) (10, 40, 56, 61, 63).”
BackgroundLi, X., Montine, K. S., Keene, C. D., & Montine, T. J. (2015) · The FASEB Journal · doi:10.1096/fj.14-262683 · Cited by 54
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk
Rosenthal, S. L., Bamne, M. N., Wang, X., Berman, S., Snitz, B. E., Klunk, W. E., Sweet, R. A., Demirci, F. Y., Lopez, O. L., & Kamboh, M. I. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.012 · Cited by 53
“early-onset neurodegeneration (Paloneva et al., 2002; Sorgana et al., 2003).”
BackgroundGuerreiro, R., Bras, J., Hardy, J., & Singleton, A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu203 · Cited by 55
“It is thought to have an antiinflammatory role in the brain (49).”
Metadata
- Authors
- Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjærg, L., Konttinen, Y., & Peltonen, L.
- Affiliations
- University of Helsinki (FI)
- University of California, Los Angeles (US)
- Umeå University (SE)
- University of Washington (US)
- Hospital Universitario La Paz (ES)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Bispebjerg Hospital (DK)
- Helsinki University Hospital (FI)
- Corresponding author
- Peltonen, Leena
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 71
- Issue
- 3
- Pages
- 656-662
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC379202
- OpenAlex
- W2014200126
- Cited by
- 683
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 37 · 2021: 48 · 2020: 47 · 2019: 34 · 2018: 54 · 2017: 53 · 2016: 38 · 2015: 42 · 2014: 29 · 2013: 28 · 2012: 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3974 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Nasu-Hakola disease, TREM2, TYROBP, DAP12, receptor signaling complex, genetic heterogeneity, progressive dementia, bone cysts, recessive inheritance
- MeSH terms
- Triggering Receptor Expressed on Myeloid Cells-1, Actins, Female, Haplotypes, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phenotype, Receptors, Immunologic, RNA, Messenger, Signal Transduction, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Protein Subunits, Macromolecular Substances, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.